Loading...
Novavax, Inc.
NVV1.F•XETRA
Healthcare
Biotechnology
€5.69
€-0.33(-5.48%)
Novavax, Inc. (NVV1.F) Financial Performance & Income Statement Overview
Review Novavax, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
22.61%
↑ 22.61%
Operating Income Growth
56.06%
↑ 56.06%
Net Income Growth
65.60%
↑ 65.60%
Operating Cash Flow Growth
87.78%
↑ 87.78%
Operating Margin
32.78%
↑ 32.78%
Gross Margin
88.25%
↑ 88.25%
Net Profit Margin
38.14%
↑ 38.14%
ROE
-115.51%
↓ 115.51%
ROIC
47.24%
↑ 47.24%
Novavax, Inc. (NVV1.F) Income Statement & Financial Overview
Review Novavax, Inc.'s (NVV1.F) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $88.31M | $84.51M | $415.48M | $93.86M |
| Cost of Revenue | $36.67M | $60.62M | $36.04M | $48.81M |
| Gross Profit | $51.64M | $23.89M | $379.44M | $45.05M |
| Gross Profit Ratio | $0.58 | $0.28 | $0.91 | $0.48 |
| R&D Expenses | $104.28M | $87.16M | $106.95M | $92.68M |
| SG&A Expenses | $78.34M | $70.75M | $101.30M | $82.30M |
| Operating Expenses | $182.72M | $157.91M | $208.24M | $183.78M |
| Total Costs & Expenses | $219.39M | $218.53M | $253.37M | $232.59M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $7.58M | $4.24M | $4.14M | $4.11M |
| Depreciation & Amortization | $12.52M | $12.70M | $11.13M | $12.15M |
| EBITDA | -$53.48M | -$105.40M | $179.86M | -$129.03M |
| EBITDA Ratio | -$0.61 | -$1.25 | $0.43 | -$1.37 |
| Operating Income | -$131.08M | -$134.02M | $161.00M | -$138.73M |
| Operating Income Ratio | -$1.48 | -$1.59 | $0.39 | -$1.48 |
| Other Income/Expenses (Net) | $57.50M | $11.69M | $3.59M | -$6.56M |
| Income Before Tax | -$73.58M | -$122.33M | $164.59M | -$145.29M |
| Income Before Tax Ratio | -$0.83 | -$1.45 | $0.40 | -$1.55 |
| Income Tax Expense | $7.45M | -$1.03M | $2.21M | $2.26M |
| Net Income | -$81.03M | -$121.30M | $162.38M | -$147.55M |
| Net Income Ratio | -$0.92 | -$1.44 | $0.39 | -$1.57 |
| EPS | -$0.51 | -$0.76 | $1.11 | -$1.05 |
| Diluted EPS | -$0.51 | -$0.76 | $0.99 | -$1.05 |
| Weighted Avg Shares Outstanding | $160.24M | $160.05M | $148.38M | $139.92M |
| Weighted Avg Shares Outstanding (Diluted) | $160.24M | $160.05M | $165.85M | $139.92M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan